Kura Oncology presents new data on the potential of darlifarnib in combination with other targeted therapies to address resistance pathways in cancer at the 2025 ESMO Congress. Early clinical and preclinical data show promising results in renal cell carcinoma with a 50% objective response rate and 80% disease control rate. The company will host a virtual investor event on October 18, 2025, to discuss these findings. Darlifarnib also shows antitumor activity in HRAS-mutant solid tumors and in combination with cabozantinib in RCC patients. Tipifarnib in combination with alpelisib demonstrates robust activity in PIK3CA-altered head and neck squamous cell carcinoma.

Read more at GlobeNewswire: Kura Oncology Announces Preliminary Data from Its Farnesyl